Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Expert Opin Pharmacother. 2022 Oct;23(14):1629-1640. doi: 10.1080/14656566.2022.2125302. Epub 2022 Sep 21.
Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide. It is among the most difficult cancers to treat, and 5-year survival rates remain low. Standard therapies for glioblastoma include surgical resection, radiation therapy and systemic chemotherapy.
We conducted a search of the literature on therapeutic options for glioblastoma on Pubmed. We also searched abstracts from the American Society of Clinical Oncology, Society for Neuro-Oncology, European Association of Neuro-Oncology and American Association for Cancer Research. We also searched the U.S. National Library of Medicine clinical trials database. We discuss therapeutic options for newly diagnosed glioblastoma, mainly temozolomide, lomustine and tumor treating fields (TTF). Lastly, we discuss therapeutics for recurrent glioblastomas and agents under investigation in clinical trials.
Enrollment in clinical trials is encouraged for both newly diagnosed and recurrent glioblastoma patients. The standard post-operative treatment for newly diagnosed glioblastoma patients is a combination of radiotherapy and temozolomide. TTF devices can be used in conjunction with temozolomide. Available standard therapies for recurrent glioblastoma include nitrosureas, bevacizumab and temozolomide rechallenge, as well as TTF devices. Agents that are being evaluated in clinical trials include novel targeted therapies, novel chemotherapies, and immunotherapies.
胶质母细胞瘤是一种恶性原发性脑肿瘤，全球每年约有 25 万名新患者。它是最难治疗的癌症之一，5 年生存率仍然很低。胶质母细胞瘤的标准治疗包括手术切除、放射治疗和全身化疗。
我们在 Pubmed 上搜索了胶质母细胞瘤治疗选择的文献。我们还检索了美国临床肿瘤学会、神经肿瘤学会、欧洲神经肿瘤学会和美国癌症研究协会的摘要。我们还检索了美国国立医学图书馆的临床试验数据库。我们讨论了新诊断胶质母细胞瘤的治疗选择，主要是替莫唑胺、洛莫司汀和肿瘤治疗电场（TTF）。最后，我们讨论了复发性胶质母细胞瘤的治疗方法以及临床试验中正在研究的药物。
鼓励新诊断和复发性胶质母细胞瘤患者参加临床试验。新诊断胶质母细胞瘤患者术后的标准治疗是放疗联合替莫唑胺。TTF 设备可与替莫唑胺联合使用。复发性胶质母细胞瘤的现有标准治疗包括亚硝脲类药物、贝伐单抗和替莫唑胺再挑战以及 TTF 设备。正在临床试验中评估的药物包括新型靶向治疗药物、新型化疗药物和免疫疗法。
